ICoronavirus, i-Covid-19 Vaccine Covaxin Ukuvuselelwa Kwamuva: I-Covaxin yeBharat Biotech

I-covid 19

I-Covaxin ye-Bharat Biotech ingumuthi wokugomela i-COVID-19 ongasasebenzi owenziwe eNdiya. Nazi ezinye zezibuyekezo zakamuva ku-Covaxin:

  • Ukusebenza: Kudatha yesilingo sesikhashana somtholampilo, i-Covaxin ikhonjiswe ukuthi inenani lokusebenza lama-77.8% uma kuqhathaniswa namacala anezimpawu ze-COVID-19. Umuthi wokugoma ubuye wabonakala usebenza ngo-93.4% ezimweni ezinzima ze-COVID-19.
  • Ukuvunywa: I-Covaxin igunyazwe ukusetshenziswa okuphuthumayo yi-World Health Organization (WHO), futhi igunyazwe ukuthi lisetshenziswe e-India nakwamanye amazwe amaningana.
  • I-Booster dose: I-Bharat Biotech ibike ukuthi umthamo we-booster we-Covaxin uboniswe ukwandisa amazinga e-antibody kakhulu, futhi inkampani ihlela ukwenza uhlolo lomtholampilo lwesigaba sesi-3 ukuhlola ukuphepha nokusebenza komthamo wesithathu womgomo.
  • umthamo Production: I-Bharat Biotech ikhulise umthamo wayo wokukhiqiza i-Covaxin, ngenhloso yokukhiqiza imithamo eyibhiliyoni engu-1 yomgomo minyaka yonke. Inkampani iphinde yasayina izivumelwano namanye amazwe amaningana zokuhlinzeka nge-Covaxin.
  • Okuhlukahlukene: I-Bharat Biotech ibike ukuthi i-Covaxin iyasebenza ekulweni nohlobo lwe-Delta lwaleli gciwane, okumanje liyinkinga enkulu emhlabeni jikelele.

Sekukonke, i-Covaxin ibonise imiphumela ethembisayo ezivivinyweni zomtholampilo futhi igunyazelwe ukusetshenziswa okuphuthumayo emazweni amaningana.